Can Abbott Laboratories’s (ABT) hike of 0.32% in a week be considered a lucky break?

On Friday, Abbott Laboratories (NYSE: ABT) opened lower -0.57% from the last session, before settling in for the closing price of $134.00. Price fluctuations for ABT have ranged from $99.71 to $141.23 over the past 52 weeks.

A company in the Healthcare sector has jumped its sales by 6.15% annually for the last half of the decade. Company’s average yearly earnings per share was noted 10.45% at the time writing. With a float of $1.73 billion, this company’s outstanding shares have now reached $1.74 billion.

In an organization with 114000 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 55.89%, operating margin of 16.97%, and the pretax margin is 17.37%.

Abbott Laboratories (ABT) Insider and Institutional Ownership

A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Abbott Laboratories is 0.67%, while institutional ownership is 78.97%. The most recent insider transaction that took place on Apr 30 ’25, was worth 337,116. In this transaction Director of this company sold 2,600 shares at a rate of $129.66, taking the stock ownership to the 34,058 shares. Before that another transaction happened on Apr 30 ’25, when Company’s Director proposed sale 2,600 for $129.66, making the entire transaction worth $337,116.

Abbott Laboratories (ABT) Latest Financial update

According to the Wall Street analysts, stocks earnings will be around 10.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.34% during the next five years compared to 29.98% growth over the previous five years of trading.

Abbott Laboratories (NYSE: ABT) Trading Performance Indicators

Check out the current performance indicators for Abbott Laboratories (ABT). In the past quarter, the stock posted a quick ratio of 1.27. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.47. Likewise, its price to free cash flow for the trailing twelve months is 34.82.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 7.71, a number that is poised to hit 1.25 in the next quarter and is forecasted to reach 5.68 in one year’s time.

Technical Analysis of Abbott Laboratories (ABT)

Let’s dig in a bit further. During the last 5-days, its volume was 5.59 million. That was inferior than the volume of 7.08 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 65.98%. Additionally, its Average True Range was 3.11.

During the past 100 days, Abbott Laboratories’s (ABT) raw stochastic average was set at 73.69%, which indicates a significant increase from 63.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 11.84% in the past 14 days, which was lower than the 23.39% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $130.48, while its 200-day Moving Average is $120.18. However, in the short run, Abbott Laboratories’s stock first resistance to watch stands at $134.41. Second resistance stands at $135.58. The third major resistance level sits at $136.19. If the price goes on to break the first support level at $132.63, it is likely to go to the next support level at $132.02. The third support level lies at $130.85 if the price breaches the second support level.

Abbott Laboratories (NYSE: ABT) Key Stats

There are currently 1,739,836K shares outstanding in the company with a market cap of 231.82 billion. Presently, the company’s annual sales total 41,950 M according to its annual income of 13,402 M. Last quarter, the company’s sales amounted to 10,358 M and its income totaled 1,325 M.